In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Rising Leaders Innovation Business Strategies

Gedea Champions Both Women’s Health And The Fight Against Antibiotic Resistance

Exclusive Interview With CEO Annette Säfholm

  • Analysis

Executive Summary

Gedea Biotech is developing an antibiotic-free drug which could significantly improve the treatment of bacterial vaginosis. In Vivo spoke with CEO Annette Säfholm, a 2021 Rising Leader. 

You may also be interested in...



NICE Tackles Antibiotic Resistance In New UK Guidance

New final guidance from NICE explains how best to avoid the risk of antibiotic resistance in patients with community- and hospital-acquired pneumonia.

Biotech Foundations: Networks And Lab Space Are As Crucial As Funding

BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies. 

Lithuania Caps Off Decade Of Growth With Stellar 2020

Lithuania’s life sciences sector has harnessed the country’s talent, infrastructure and government support to realize a decade of unprecedented growth. With the industry now maturing, can the Baltic state overcome challenges to become a significant European player?

Table

View full table

Topics

Related Companies

Tags:
Rising Leaders Innovation Business Strategies
Latest Headlines

Industry Leaderboard Gains And Dips Were Still Marked By COVID-19

The New Antibodies Revolutionizing Medicine

Macro Challenges Make Calls On Newly Resilient Medtechs

Will Medicare Price Negotiation Stop Post-Approval R&D?

See All
UsernamePublicRestriction

Register

IV124817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By